• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

ViaCyte’s Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

1/31/2013

 
Via ViaCyte:
San Diego, California, January 31, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company’s already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad technology platform.

VC-01 is a very promising, development-stage product that consists of pancreatic precursor cells (called PEC-01) derived from a proprietary human embryonic stem cell line and encapsulated in a proprietary, immune isolating medical device (the ENCAPTRA® device). When implanted under the skin in suitable animal models, the cells further differentiate into insulin producing and other endocrine cells that regulate blood glucose in a manner similar or identical to a normal pancreas. If VC-01 performs in humans as it has in animal studies, it could effectively cure type 1 diabetics and be an important new therapy for insulin dependent type 2 diabetics.

ViaCyte’s significant intellectual property portfolio now includes over 300 issued patents and pending applications related to the growth, directed differentiation and use of human pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem cells. This portfolio includes 51 issued U.S. and foreign patents specifically directed to the Company’s VC-01 product. In addition to the protection afforded by patents, the Company also relies on significant proprietary know-how to develop its product offerings.

Read more: http://viacyte.com/press-releases/viacytes-role-as-a-leading-cell-therapy-company-bolstered-with-the-issuance-of-20-patents-in-2012/

TetraLogic Pharmaceuticals Announces Decision to Grant Japanese Patent on Birinapant 

1/28/2013

 
Via TetraLogic:
MALVERN, Pa., January 28, 2013 – TetraLogic Pharmaceuticals today announced that the Japan 
Patent Office (JPO) issued a Decision to Grant the company a patent that claims birinapant, a Smac 
mimetic currently in Phase 2 clinical studies for the treatment of various cancers. The allowed Japanese 
patent application, JP 2007-557249, has claims directed to the class of Smac mimetics that encompasses 
birinapant as a new chemical entity (NCE) and to drug products comprising birinapant and structurally 
related Smac mimetics. 
 
A Decision to Grant is issued after the JPO makes a determination that a patent can be granted from an 
application. The issued patent would have a term that expires no earlier than in 2026. 
 
This application is part of an expanding international patent portfolio for TetraLogic with Japan being the 
ninth country to acknowledge the patentability of the company’s Smac mimetics. Others include the 
United States, People's Republic of China, Eurasian Patent Office (which incudes Russia), Australia, 
India, Mexico, Singapore and South Africa. Additional counterpart patent applications are pending 
examination in Europe, Brazil, Canada, Israel, and Korea. 

Read more: http://files.shareholder.com/downloads/AMDA-2C8MW4/2989657472x0x707411/04e4f92e-1b68-43e7-840e-d6480321c1cf/707411.pdf

Next Steps in Potential Stem Cell Therapy for Diabetes

1/10/2013

 
Via UC San Diego News Center:
Type 1 and type 2 diabetes results when beta cells in the pancreas fail to produce enough insulin, the hormone that regulates blood sugar.  One approach to treating diabetes is to stimulate regeneration of new beta cells. 

There are currently two ways of generating endocrine cells (cell types, such as beta cells, that secrete hormones) from human embryonic stem cells, or hESCs: either generating the cells in vitro in culture or transplanting immature endocrine cell precursors into mice.

Researchers from the University of California, San Diego School of Medicine, collaborating with scientists from San Diego-based biotech company ViaCyte, Inc., looked at the differences and similarities between these two types of hESC-derived endocrine cell populations and primary human endocrine cells, with the longer-term goal of developing new stem cell therapies for diabetes.

Read more: http://ucsdnews.ucsd.edu/pressrelease/next_steps_in_potential_stem_cell_therapy_for_diabetes

    Archives

    October 2023
    September 2023
    September 2022
    August 2022
    June 2022
    May 2022
    February 2022
    January 2022
    December 2021
    May 2021
    April 2021
    February 2021
    January 2021
    December 2020
    November 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - [email protected]
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics